Regeneron R1033 (R1033-HV-1223), A randomized, double-blind, placebo-controlled, parallel group, multicenter study of the effects of repeated doses of subcutaneous REGN1033 treatment with and without exercise, on safety, body composition, muscle strength and stair climb power in male and female subjects aged 60 and older.PI: Pahor, Marco, MD
PI: Manini, Todd, Ph.D.
Funding Agency: Regeneron Pharmaceuticals, Inc.
Start Date: Jul 1, 2013
End Date: Mar 31, 2015
Core Support: Clinical Translational Research Core